Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis

Fertility and Sterility

Volumn 94, Issue 1, 2010, Pages 52-57

  Bourlev, Vladimir ^a,b   Iljasova, Natalia ^a,b   Adamyan, Leyla ^b   Larsson, Anders ^a   Olovsson, Matts ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Ang 2; angiogenesis; angiogenin; Endometriosis; sVEGFR 1; sVEGFR 2; VEGF

Indexed keywords

ANALGESIC AGENT; ANGIOGENIN; ANGIOPOIETIN 2; CONTRACEPTIVE AGENT; GESTAGEN; GONADORELIN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENDOMETRIOSIS; FEMALE; HUMAN; HYSTERECTOMY; NEOVASCULARIZATION (PATHOLOGY); PELVIS PAIN SYNDROME; PERITONEAL FLUID LEVEL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THERAPY EFFECT; UTERUS SURGERY;

ANGIOPOIETIN-2; ASCITIC FLUID; BIOLOGICAL MARKERS; DOWN-REGULATION; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 77952551462     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.02.019     Document Type: Article

References (51)

1. Goldman M.B., and Cramer D.W. The epidemiology of endometriosis. Prog Clin Biol Res 323 (1990) 15-31
2. Vinatier D., Orazi G., Cosson M., and Dufor P. Theories of endometriosis. Eur J Obstet Gynecol Reprod Biol 96 (2001) 21-34
3. Nisolle M., and Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril 68 (1997) 585-596
4. Cullen T.S. The distribution of adenomyomas containing uterine mucosa. Arch Surg 1 (1920) 215-283
5. Koninckx P.R., Meuleman C., Demeyere S., Lesaffre E., and Cornillie F.J. Suggestive evidence that endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 55 (1991) 759-765
6. Garry R. Is insulin resistance an essential component of PCOS? The endometriosis syndromes: a clinical classification in the presence of aetiological confusion and therapeutic anarchy. Hum Reprod 19 (2004) 760-768
7. Chapron C., Chopin N., Borghese B., Malartic C., Decuypere F., and Foulot H. Surgical management of deeply infiltrating endometriosis: an update. Ann N Y Acad Sci 1034 (2004) 326-337
8. Kwok A., Lam A., and Ford R. Deeply infiltrating endometriosis: implications, diagnosis and management. Obstet Gynecol Surv 56 (2001) 168-177
9. Fauconnier A., and Chapron C. Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum Reprod Update 11 (2005) 595-606
10. Taylor R.N., Lebovic D.I., and Mueller M.D. Angiogenic factors in endometriosis. Ann N Y Acad Sci 955 (2002) 89-100
11. Kyama C.M., Debrock S., Mwenda J.M., and D'Hooghe T.M. Potential involvement of the immune system in the development of endometriosis. Reprod Biol Endocrinol 1 (2003) 123
12. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 6 (2000) 45-55
13. Bourlev V., Volkov N., Pavlovitch S., Lets N., Larsson A., and Olovsson M. The relationship between micro vessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 132 (2006) 503-511
14. McLaren J., Prentice A., Charnock-Jones D.S., and Smith S.K. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 11 (1996) 220-223
15. Gagne D., Page M., Robitaille G., Hugo P., and Gosselin D. Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Hum Reprod 18 (2003) 1674-1680
16. Artini P.G., Ruggiero M., Monteleone P., Carpi A., Cristello F., Cela V., et al. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother 62 (2008) 373-377
17. Xavier P., Belo L., Beires J., Rebelo I., Martinez-de-Oliveira J., Lunet N., et al. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 273 (2006) 227-231
18. Barleon B., Reusch P., Totzke F., Herzog C., Keck C., Martiny-Baron G., et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4 (2001) 143-154
19. Molskness T.A., Stouffer R.L., Burry K.A., Gorrill M.J., Lee D.M., and Patton P.E. Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women. Hum Reprod 19 (2004) 822-830
20. Wikstrom A.K., Larsson A., Eriksson U.J., Nash P., Norden-Lindeberg S., and Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 109 (2007) 1368-1374
21. Wierzbowska A., Robak T., Wrzesien-Kus A., Krawczynska A., Lech-Maranda E., and Urbanska-Rys H. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw 14 (2003) 149-153
22. Fett J.W., Strydom D.J., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24 (1985) 5480-5486
23. Suzumori N., Zhao X.X., and Suzumori K. Elevated angiogenin levels in the peritoneal fluid of women with endometriosis correlate with the extent of the disorder. Fertil Steril 82 (2004) 93-96
24. Steff A.-M., Gagné D., Pagé M., Rioux A., Hugo P., and Gosselin D. Serum concentrations of insulin-like growth factor-1, soluble tumor necrosis factor receptor-1 and angiogenin in endometriosis patients. Am J Reprod Immunol 51 (2004) 166-173
25. Geva E., and Jaffe R.B. Role of angiopoietins in reproductive tract angiogenesis. Obstet Gynecol Surv 55 (2000) 511-519
26. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 4 277 (1997) 48-50
27. Fiedler U., and Augustin H.G. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27 (2006) 552-558
28. Roviezzo F., Tsigkos S., Kotanidou A., Bucci M., Brancaleone V., Cirino G., et al. Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 314 (2005) 738-744
29. Lemieux C., Maliba R., Favier J., Théorêt J.F., Merhi Y., and Sirois M.G. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 105 (2005) 1523-1530
30. Krikun G., Schatz F., Finlay T., Kadner S., Mesia A., Garrets R., et al. Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem Biophys Res Commun 275 (2000) 159-163
31. Li X.F., Charnock-Jones D.S., Zhang E., Hiby S., Malik S., Day K., et al. Angiogenic growth factor messenger ribonucleic acids in uterine aural killer cells. J Clin Endocrinol Metab 86 (2001) 1823-1834
32. Hewett P., Nijjar S., Shams M., Morgan S., Gupta J., and Ahmed A. Down-regulation of angiopoietin-1 expression in menorrhagia. Am J Pathol 160 (2002) 773-780
33. Hirokoshi K., Maeshima Y., Kobayashi K., Matsuura E., Sugiyama H., Yamasaki Y., et al. Increase of serum angiopoietin-2 during pregnancy is suppressed in women with preeclampsia. Am J Hypertens 18 (2005) 1181-1188
34. American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine Classification of Endometriosis. Fertil Steril 67 (1996) 817-821
35. Noyes R.W., Hertig A.T., and Rock J. Dating the endometrial biopsy. Fertil Steril 1 (1950) 2-25
36. Donnez J., Smoes P., Gillerot S., Casanas-Roux F., and Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 13 (1998) 1686-1690
37. Bourlev V., Larsson A., and Olovsson M. Elevated levels of fibroblast growth factor-2 in serum from women with endometriosis. Am J Obstet Gynecol 194 (2006) 755-759
38. Khan K.N., Masuzaki H., Fujishita A., Kitajima M., Sekine I., and Ishimaru T. Higher activity by opaque endometriotic lesions than nonopaque lesions. Acta Obstet Gynecol Scand 83 (2004) 375-382
39. Machado D.E., Abrao M.S., Berardo P.T., Takiya C.M., and Nasciutti L.E. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 90 (2008) 148-155
40. Futami R., Miyashita M., Nomura T., Makino H., Matsutani T., Sasajima K., et al. Increased serum vascular endothelial growth factor following major surgical injuri. J Nippon Med Res 74 (2007) 223-229
41. Belizon A., Balik E., Horst P., Feingold D., Arnell T., Azarani T., et al. Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc 22 (2008) 287-297
42. Bedaiwy M.A., and Falcone T. Laboratory testing for endometriosis. Clin Chim Acta 340 (2004) 41-56
43. Potlog-Nahari C., Stratton P., Winkel C., Widra E., Sinaii N., Connors S., et al. Urine vascular endothelial growth factor-A is not a useful marker for endometriosis. Fertil Steril 81 (2004) 1507-1512
44. Mints M., Blomgren B., Falconer C., Fianu-Jonasson A., and Palmblad J. Microvascular density, vascular endothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia. Fertil Steril 84 (2005) 692-700
45. Malik S., Day K., Perrault I., Charnock-Jones D.S., and Smith S.K. Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual endometrium and effluent in women with menorrhagia. Hum Reprod 21 (2006) 2158-2166
46. Chung H.C., Rha S.Y., Ahn J.B., Shim K.Y., Yoo N.C., Kim J.H., et al. Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Int J Mol Med 4 (1998) 465-470
47. Artini P.G., Cristello F., Monti M., Cela V., Battaglia C., D'Ambrogio G., et al. Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecol Endocrinol 21 (2005) 50-56
48. Cho S.H., Oh Y.J., Nam A., Kim H.Y., Park J.H., Kim J.H., et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. Am J Reprod Immunol 58 (2007) 497-504
49. Jingting C., Yangde Z., Yi Z., Mengxiong L., Rong Y., Yu Z., et al. Expression of heparanase and angiopoietin-2 in patients with endometriosis. Eur J Obstet Gynecol Reprod Biol 136 (2008) 199-209
50. Ebos J.M., Bocci G., Man S., Thorpe P.E., Hicklin D.J., Zhou D., et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2 (2004) 315-326
51. Chaiworapongsa T., Romero R., Gotsch F., Espinoza J., Nien J.K., Goncalves L., et al. Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med 21 (2008) 41-52